


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
Ozaki et al.	§	Group Art Unit: Not Assigned
	§	
	§	Examiner: Not Assigned
Serial No.: Not Assigned	§	
Confirmation No.:	§	Att'y Docket: 13240.0004.CNUS01
	§	
Filed: December 2, 2003	§	Client Docket:
	§	F5-01F03832/KA016-1US
For: DIAGNOSTIC DRUGS FOR AUTO	§	
IMMUNE DISEASES	§	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

<p style="text-align: center;">CERTIFICATE OF MAILING 37 C.F.R. 1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:</p> <p>December 2, 2003  Signature</p>

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 01-2508/13240.0004.CNUS01/BNT.

This application is a continuation application of Serial No. 09/214,881, filed on June 7, 1999, which was a 35 U.S.C. 371 national phase filing of international application PCT/JP97/01647, filed May 15, 1997, which claimed priority to Japanese Patent Applications 8/187945, filed July 17, 1996, and 8/266431, filed October 7, 1996, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98(d), copies of listed documents A1 and C1-C10 are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/214,881.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Christopher J. Buntel, Ph.D.
Reg. No. 44,573
Customer No. 23369
ATTORNEY FOR ASSIGNEE,
KANEKA CORPORATION

Howrey Simon Arnold & White, LLP
750 Bering Drive
Houston, TX 77057-2198
(713) 787-1569

December 2, 2003

Form PTO-1449 (modified)		Atty. Docket No. 13240.0004.CNUS01	Serial No.
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ozaki et al.	
		Filing Date: December 2, 2003	Group:
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>N/A</i>	Other Art <i>See Pages 2 & 3</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing date of App.
	A1	4,281,061	07/28/1981	Zuk et al.	435	188	07/27/79
	A2						
	A3						
	A4						
	A5						
	A6						
	A7						
	A8						
	A9						
	A10						
	A11						
	A12						
	A13						
	A14						
	A15						
	A16						
	A17						
	A18						
	A19						
	A20						

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 13240.0004.CNUS01	Serial No.
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ozaki et al.	
		Filing Date: December 2, 2003	Group:
U.S. Patent Documents See Page 1	Foreign Patent Documents N/A	Other Art See Pages 2 & 3	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	International Search Report dated October 14, 1997
	C2	Ayer, L. M. et al. Arthritis & Rheumatism, "Antibodies to HMG Proteins in Patients with Drug-Induced Autoimmunity", Volume 37, Number 1, January 1995, pp 98-103
	C3	Adachi, Yoshifumi et al. Journal of Chromatography, "Efficient Large-Scale Purification of Non-Histone Chromosomal Proteins HMG1 and HMG2 by using Polybuffer-Exchanger" PBE94, 530 1990, pp. 39-46
	C4	Yoshida, Michiteru et al. Journal of Biochemistry, "Unwinding of DNA by Nonhistone Chromosomal Protein HMG1(I+2) from Pig Thymus as Determined with Endonuclease", 95, 1984, pp. 117-124
	C5	Clayton, et al. "Measurement of antibody to poly (adenosine diphosphate-ribose): its diagnostic value in systemic lupus erythematosus," 1984, pp. 263-271, Clin. exp. Immunol.
	C6	Yung, et al. "Sex-Specific Differences in T Cell Homing May Explain Increased Disease Severity in Female Mice," July 1997, pp. 1334-1343, Volume 40, No. 7, Arthritis & Rheumatism
	C7	Neuer et al., "Autoantibodies to the Chromosomal Protein HMG-17 in Juvenile Rheumatoid Arthritis," April 1992, pp. 472-475, Volume 35, No. 4, Arthritis & Rheumatism
	C8	Bettina Witteman et al., "Autoantibodies to Nonhistone Chromosomal Proteins HMG-1 and MHG-2 in Sera of Patients with Juvenile Rheumatoid Arthritis," Arthritis and Rheumatism, Volume 33, No. 9, pp. 1378-1383, (1990)
	C9	P.M. Colman; "Effects of amino acid sequences changes on antibody-antigen interactions;" 55 th Forum in Immunology; Volume 145; pp. 33-36 (1994)
	C10	Ayer et al.; "Antibodies to High Mobility Group Proteins in Systemic Sclerosis;" Journal of Rheumatology; Volume 21, No. 11; pp. 2071-2075 (1994)
	C11	European Examination Report; August 28, 2003
	C12	J. Sobajima, S. Ozaki, T. Okazaki, F. Osakada, S. Sumita, K. Mori & K. Nakao "Anti-Neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis; anti-cathepsin G and a novel antibody correlate with a refractory type"; 1996 Blackwell Science Ltd, Clinical and Experimental Immunology; pp. 120-124

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 13240.0004.CNUS01	Serial No.
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ozaki et al.	
		Filing Date: December 2, 2003	Group:
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>N/A</i>	Other Art <i>See Pages 2 & 3</i>	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C13	"Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis;" Wolfgang L. Gross, Elena Csernok and Udo Helmchen; 1995 APMIS 103, pp. 81-97

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)